Research

Cellular

GLP-1 medicines may contribute to decreased cancer incidence.

Consider the potential cancer risk reduction when prescribing GLP-1 medicines.

StrongQualifiesmedium confidence
thus improving outcomes for people with type 2 diabetes and obesity and potentially contributing to decreased cancer incidence.
Julian M. Yabut et al. · Nature Cancer · 2026

Why this rating

The claim is based on data from trials and registries.

Source

Glucagon-like peptide-1 medicines and cancer

Julian M. Yabut et al. · Nature Cancer · 2026

DOI 10.1038/s43018-025-01110-1

otherCited 4×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →